💬In plain words
What the trial is, and whether it could suit you
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia caused by E. coli. It will also measure cefotetan minimum inhibitory concentration (MIC) distributions and cefotetan trough serum concentrations.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria (clinical cohort):
* Identified within 72 hours of inpatient antibiotic administration for acute illness.
* Patient or legally authorized representative are able to provide informed consent for participation in the study.
* Monomicrobial E. coli bacteremia.
* Isolate susceptible to both ertapenem and cefotetan (ESBL infections) or ceftriaxone and cefotetan (non-ESBL infections).
Exclusion Criteria (clinical cohort):
* Allergy to cefotetan.
* History of cephalosporin-associated hemolytic anemia.
* Allergy to ertapenem or meropenem (among patients with ESBL E. coli infections).
* Allergy to ceftriaxone (among patients with non-ESBL E. coli infections). Includes allergy to antibiotics with a similar structure expected to confer cross reactivity to ceftriaxone (cefotaxime, cefpodoxime, ceftazidime).
* Any bacteremia with the same organism in the previous 30 days.
* Pregnant or breastfeeding.
* Neutropenia (absolute neutrophil count \<500 cells/microL), current or anticipated during acute illness.
* Stem cell transplant or hematologic malignancy receiving chemotherapy.
* Severe illness, including shock and/or intensive care unit admission.
* Inability to complete at least 72 hours of appropriate parenteral therapy, including at least 1 dose cefotetan for patients randomized to the treatment arm or at least 1 dose of appropriate parenteral therapy following randomization for patients assigned to the standard of care arm.
HealthTeky